Caricamento...
Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting
Trastuzumab has had a major impact on outcomes in HER2-positive breast cancer, but innate or acquired resistance to it is recognized as a problem that can limit its effectiveness. Given its locus of action, the oral tyrosine kinase inhibitor lapatinib would be expected to counteract many of the prop...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4115768/ https://ncbi.nlm.nih.gov/pubmed/25083500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2227-684X.2013.09.01 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|